Conversely, a small retrospective study reported the clinical benefit of anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4)/PD(L)1 in patients who experienced progression on PD-(L)1 with or without anti-VEGF regimens in HCC.60 This evidence concerns the gene CTLA4 and hepatocellular carcinoma.